ROCKVILLE, MD, April 22, 2024 – AcroImmune announced that its first-in-class Siglec-10 antibody has received FDA approval for clinical trials to treat solid tumors. Founders of AcroImmune, Professors Yang Liu and Pan Zheng, have conducted pioneering research in the CTLA-4 and CD24/Siglec-10 pathways. Their next-generation, differentiated CTLA-4 antibody is currently in Phase III clinical trials, while their CD24 antibody has been licensed to Merck & Co.
